Patient-Based Therapeutics
AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas



Latest News
At the 15th annual ALS Network Research Summit, held on January 16, AcuraStem's Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan Chang delivered a key presentation titled 'Development of an UNC13A ASO for ALS.'
At the 35th International Symposium on ALS/MND, held from December 6-8, 2024, at the Montreal Convention Center, AcuraStem Chief Scientific Officer Marcel van der Brug delivered a key presentation titled 'Development of an UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment for ALS.
AcuraStem announced the appointment of Marcel van der Brug, Ph.D., as Chief Scientific Officer. Dr. van der Brug is an accomplished neuroscientist with extensive expertise in neurodegenerative diseases and therapeutic development.